COMMUNIQUÉS West-GlobeNewswire

Curia et Carterra coorganisent un symposium sur les produits biologiques pour encourager la recherche en biotechnologie dans le nord-ouest du Pacifique

10/05/2024 - 14:30

ALBANY, New York et SALT LAKE CITY, 10 mai 2024 (GLOBE NEWSWIRE) -- Curia, une organisation de premier plan du domaine de la recherche, du développement et de la fabrication sous contrat, et Carterra Inc., leader [...]

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

10/05/2024 - 14:30

BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

10/05/2024 - 14:26

- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201 - Clinically meaningful tumor reduction observed at [...]

iTeos Therapeutics Announces $120 Million Registered Direct Offering

10/05/2024 - 14:24

- Led by existing investors RA Capital Management and Boxer Capital - Purchase price of $17.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro forma cash position of [...]

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

10/05/2024 - 14:24

The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the " [...]

Smart for Life to Attend Vitafoods Europe 2024: Positioned to Identify Strategic Partnerships and Potential Acquisitions

10/05/2024 - 14:00

Renowned Industry Leader and Smart for Life Board Member Heather Granato to Speak at Nutraceutical Event in Geneva, Switzerland MIAMI, May 10, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for [...]

Mobile-health Network Solutions Expands Services to Malaysia

10/05/2024 - 14:00

SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced the establishment of a subsidiary in [...]

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

10/05/2024 - 14:00

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

10/05/2024 - 14:00

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical [...]

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

10/05/2024 - 14:00

FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of [...]

PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

10/05/2024 - 13:59

The FDA Assigned Goal Date is October 29, 2024 TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today [...]

First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market

10/05/2024 - 13:55

BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]

Ocugen to Present at May 2024 Investor Conferences

10/05/2024 - 13:45

MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

10/05/2024 - 13:17

GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on [...]

Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT

10/05/2024 - 13:00

- Data show that AXV-101 halts photoreceptor and outer nuclear retinal layer (ONL) degeneration in a dose-dependent manner - - Company to initiate clinical studies in 1H 2025 to treat blindness and progress AXV-101 [...]

Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024

10/05/2024 - 13:00

Management to host conference call and webcast at 8:30am ET PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial [...]

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

10/05/2024 - 13:00

DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 [...]

Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting

10/05/2024 - 13:00

– Significant advancements in engineering neutralizing antibody (NAb) evasion properties into receptor-targeted capsids, including novel TfR1-binding capsids, demonstrate increased opportunities to treat AAV [...]

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

10/05/2024 - 13:00

Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD [...]